The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.
For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.
For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, please access the NCCN ORP pages at NCCN.org/clinical_trials/ clinicians.asp.
Highlights of the NCCN Oncology Research Program
The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.
NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
NCCN-sponsored studies funded through the grant mechanism are highlighted below. This trial has a dose escalation component and expansion cohort at the maximum tolerated dose (MTD). The dose-escalation portion will include patients with solid tumors; the expansion cohort is limited to those with differentiated thyroid cancer. A total of 6 dose levels are defined for the phase I study. Three dose levels of pazopanib (400 mg, 600 mg, and 800 mg qd) with the GSK1120212 dose held constant (1 mg qd) will be tested, followed by 3 dose levels where the pazopanib dose is held constant (800 mg qd) and GSK 1120212 is escalated (1 mg, 1.5 mg, and 2 mg qd). Three patients will be treated per dose level in a standard 3 + 3 dose escalation design. The MTD is defined as the highest dose at which 1 or fewer dose-limiting toxicities (DLTs) are observed in 6 patients. A total of 6 patients will be treated at the MTD. The target toxicity with this type of design is less than 30%. At least 3 patients must be treated for 4 weeks without the development of a DLT prior to treating a new cohort at a higher dose level. Primary Objective:
• Determine the safety and toxicity of combination pazopanib and GSK 1120212 in patients with solid tumors and advanced thyroid cancer, and identify the MTD for phase II study. Secondary Objectives: Secondary objectives and correlative studies will be evaluated only in the expansion cohort, which will comprise of patients with advanced thyroid cancer being treated at the MTD.
• Response rate: preliminary efficacy of this treatment combination will be assessed by the objective response rate at 6 months.
• Progression-free survival (PFS): will be a secondary measure of efficacy and will be defined from the date of study entry to the date of progression or death. The median PFS will be compared with a historical median, estimated to be 11.7 months.
• Pharmacokinetic (PK) data, pharmacodynamic (PD) markers, tumor genotype and subtype: exploratory end points include correlation of PK data with radiographic response, PD markers, and the impact of tumor histologic subtype and tumor genotype on radiographic response. Maintenance phase: beginning 8 weeks after course 4 of the induction phase, patients receive ofatumumab intravenously on day 1 and bortezomib subcutaneously on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, and then every 3 months for 5 years. Primary Objective:
• Determine overall response rate (complete remission [CR] + partial response [PR] + minor response) of OB. Secondary Objectives:
• Determine CR, near CR, very good partial remission, and PR rates per new criteria.
• Determine 5-year PFS.
• Determine time to progression and duration of response to OB.
• Determine safety of OB.
• Conduct laboratory correlates. Contact: Roswell Park • 877-275-7724 • AskRPCI@roswellpark.org ClinicalTrials.gov Identifier: NCT01536067
